{
    "clinical_study": {
        "@rank": "55593", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of reserpine for the\n      treatment of cocaine dependence."
        }, 
        "brief_title": "Reserpine for the Treatment of Cocaine Dependence - 1", 
        "completion_date": "May 2003", 
        "condition": [
            "Cocaine-Related Disorders", 
            "Substance-Related Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cocaine-Related Disorders", 
                "Substance-Related Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess the efficacy and safety of reserpine in reducing cocaine use in subjects with\n      cocaine dependence. This is a double-blind, placebo-controlled, parallel-group design with a\n      2 week baseline period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Be at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; treatment seeking\n        individuals; have the ability to understand and provide written informed consent; females\n        of child bearing potential using appropriate birth control method\n\n        Exclusion Criteria:\n\n        Additional criteria available during screening at the site."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "140", 
        "firstreceived_date": "April 5, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00024869", 
            "nct_id": "NCT00033033", 
            "org_study_id": "NIDA-CTO-0001-1"
        }, 
        "intervention": {
            "intervention_name": "Reserpine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Reserpine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 15, 2008", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Boston University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45220"
                    }, 
                    "name": "Cincinnati VA Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45428"
                    }, 
                    "name": "Dayton VA Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence", 
        "overall_official": {
            "affiliation": "Cincinnati VA Medical Center", 
            "last_name": "Eugene Somoza, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Federal Government"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_outcome": [
            {
                "measure": "Cocaine use"
            }, 
            {
                "measure": "Addiction severity"
            }, 
            {
                "measure": "Cocaine withdrawal"
            }, 
            {
                "measure": "Adverse events"
            }, 
            {
                "measure": "Clinical improvement"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00033033"
        }, 
        "responsible_party": {
            "name_title": "Liza Gorgon / Clinical Trials Specialist", 
            "organization": "NIDA"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "collaborator": {
                "agency": "Cincinnati VA Medical Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2008"
    }, 
    "geocoordinates": {
        "Boston University Medical Center": "42.358 -71.06", 
        "Cincinnati VA Medical Center": "39.103 -84.512", 
        "Dayton VA Medical Center": "39.759 -84.192"
    }
}